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ABSTRACT
The relation between Epstein-Barr virus (EBV) DNA load and clinical course of 
patients with chronic lymphocytic leukemia (CLL) is unknown. We assessed EBV 
DNA load by quantitative PCR at CLL presentation in mononuclear cells (MNC) of 220 
prospective patients that were enrolled and followed-up in two major Institutions. 
In 20 patients EBV DNA load was also assessed on plasma samples. Forty-one age-
matched healthy subjects were tested for EBV DNA load on MNC. Findings were 
validated in an independent retrospective cohort of 112 patients with CLL. EBV DNA 
load was detectable in 59%, and high (≥2000 copies/µg DNA) in 19% of patients, 
but it was negative in plasma samples. EBV DNA load was significantly higher in CLL 
patients than in healthy subjects (P < .0001). No relation was found between high 
EBV load and clinical stage or biological variables, except for 11q deletion (P = .004), 
CD38 expression (P = .003), and NOTCH1 mutations (P = .05). High EBV load led 
to a 3.14-fold increase in the hazard ratio of death and to a shorter overall survival 
(OS; P = .001). Poor OS was attributable, at least in part, to shorter time-to-first-
treatment (P = .0008), with no higher risk of Richter’s transformation or second 
cancer. Multivariate analysis selected high levels of EBV load as independent predictor 
of OS after controlling for confounding clinical and biological variables. EBV DNA load 
at presentation is an independent predictor of OS in patients with CLL.
INTRODUCTION
Epstein-Barr virus (EBV) is a γ-herpesvirus harbored 
by the great majority of adults worldwide, resulting in 
life-long infection [1]. Following primary infection, EBV 
remains latent in memory B-cells, and confined by EBV-
specific cytotoxic T lymphocytes in the healthy host [2]. 
However, in patients with profound immunosuppression 
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due to T-cell function impairment and/or insufficient 
antibody production, the infection may induce lytic 
replication of the EBV genome and B-cell proliferation. 
There is compelling evidence for an etiologic role of 
EBV in certain B-cell tumors including endemic Burkitt 
lymphoma [3, 4], post-transplant lymphoproliferative 
disease [3, 4], HIV-related lymphomas [5], and aggressive 
lymphomas of the elderly [6].
Chronic lymphocytic leukemia (CLL) is typically 
characterized by immunosuppression already manifest 
in the early phases of the disease [7]. Although CLL is 
not considered an EBV associated disease, CLL cells 
express the complement receptor that serves as EBV 
receptor [8]. Pre-clinical data indicate that CLL cells are 
difficult to grow after exposure to EBV [9, 10], although 
this can be achieved following cytokine activation [11] 
or by successful outgrowth of in vivo EBV infected CLL 
cells [10]. A recent epidemiological study has reported an 
association between EBV infection and risk of developing 
CLL [12]. Tarrand et al. [13] reported that LMP1 mRNA 
levels were higher in CLL patients than in healthy subjects 
(14% vs. 1% of healthy controls), suggesting that EBV 
late gene expression does occur at least in a subset of CLL 
cells. The same group reported that 38% of CLL patients 
had evidence of EBV infection by in situ hybridization 
for EBV EBER1, a small noncoding RNA species [14]. 
Furthermore, EBV infection correlated with accelerated 
clinical course, including Richter’s transformation [14-
16]. Another study showed a relation between latent EBV 
infection and CLL cases expressing IGHV4-34 B-cell 
receptor configuration [17].
With this study we show that EBV DNA load 
obtained from mononuclear cells (MNC) of patients with 
CLL at disease presentation is higher than in healthy 
controls. Increasing levels of EBV DNA load were 
significantly associated to shorter survival. 
RESULTS
EBV DNA load in MNC, sorted B-cells and 
plasma of patients with CLL, and in MNC of 
healthy subjects
EBV DNA load was detectable by real-time PCR 
(>0 copies/µg DNA) in 129 of the 220 patients (59%), and 
was high (≥2000 copies/µg DNA) in 43 of the 220 patients 
Figure 1: EBV DNA load measured as continuous variable in 41 healthy subjects compared to 220 patients with CLL. 
Each bar of the histogram corresponds to a tested patient. EBV DNA was detectable by real-time PCR (>0 copies/µg DNA) in 129 (59%) 
(patients with CLL), and in 15 (37%) healthy subjects (P < .0001)..
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(19%). Distribution of EBV DNA levels among patients 
was skewed to the right and had a peaked distribution 
(skewness 4.906, Kurtosis 33.160 by K–S test). Mean 
and median value among patients were 1625 and 192, 
respectively (standard deviation 3877; range 0-36449). In 
all five patients tested in parallel in sorted B-cells, EBV 
DNA load gave similar results to that observed in MNC 
(± 30 copies/µg DNA).
Twenty patients (10 with EBV DNA load ≥2000, 
and 10 with <2000 copies/µg DNA) were tested for EBV 
DNA load on plasma samples. All 20 resulted negative.
Viral load was significantly higher in patients with 
CLL than in healthy subjects (median value 0 copies/µg 
DNA; range 0-3234; P < .0001), as shown in Figure 1. 
EBV DNA load was not associated with any of the 
EBV serological patterns (IgG+/IgM- versus IgG+/IgM+ 
versus IgG-/IgM-). 
Patients characteristics according to EBV status
Clinical and biological characteristics of our 
patients, divided according to EBV DNA load as a 
dichotomous variable, are listed in Table 1. Basically, a 
direct association between viral load, CD38 expression (P 
= .003), presence of del11q (P = .004), and borderline with 
mutations of NOTCH1 (P = .05) was identified. There was 
a non-significant trend (P = .09) for older age in patients 
with high EBV DNA load. 
Overall, 36 of 137 patients (26%) from the learning 
set had stereotyped B-cell receptor configuration. Of them, 
five had EBV DNA load ≥ 2000 copies/µg DNA, and 31 
had EBV DNA < 2000 (22% vs 27%, respectively, P = 
.58). Subsets distribution appeared not biased between 
patients with high or low EBV DNA load.
Overall survival and time to first treatment
With a median follow-up of 54 months (range 12-
98), we registered 30 deaths in the learning set. Median 
OS has not been reached, and 5-years OS was 83% ± 
3% (Figure 2a). Patients with high EBV DNA load had a 
significant inferior OS (67% ± 8% at 5-years) than patients 
with low EBV DNA load (88% ± 3%, P = .001, Figure 
2c). Two-years TTFT was 74% ± 3% (Figure 2b). Patients 
Figure 2: Kaplan Meier plot for overall survival (OS, a) and time to first treatment (TTFT, b) of patients from the 
learning set, dichotomized according to high or low EBV DNA load (≥ vs < 2000 copies/µg DNA, c and d). Hazard ratio 
and 95% confidence interval were 3,149 (1,486-6,672) and 2,243 (1,378-3,648) for OS and TTFT, respectively.
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with high EBV DNA load had a significant inferior 2-years 
TTFT (52% ± 7%) than patients with low EBV DNA load 
(79% ± 3%, P = .01, Figure 2d). This predictive effect 
on TTFT was confirmed when the 171 patients with were 
analyzed separately (2-years TTFT 99% ± 1% for patients 
with low EBV DNA load versus 90% ± 5% for patients 
with high EBV DNA load, P = .001). 
No significant difference was observed both in terms 
of OS and TTFT in patients with 0 copies/µg of DNA and 
those with <2000 copies/µg DNA, suggesting that the 
2000 cut-off might be appropriate for defining high values. 
No impact of different front-line treatment approaches was 
evident on the EBV DNA predictive power.
Among other prognostic variables, univariate 
analysis recognized Binet A vs B or C (P < .0001), CD38, 
ZAP70, and CD49d expression (P = .002, P = .009, P = 
.01, respectively), IGHV mutational status (P < .0001), 
presence of del17p/P53 gene mutations (P = .0005), and 
NOTCH1 gene mutations (P = .03), as significantly related 
to TTFT. In terms of OS, all these variables maintained 
prognostic significance in univariate analysis except for 
ZAP70, CD49d and CD38 expression (the latter being 
borderline, P = .06), NOTCH1 mutations (P = .14), and 
Binet stage (P = .18).
Mutations of SF3B1, MYD88, and BIRC3 did not 
reach statistical significance due to the low number of 
mutated patients at CLL diagnosis in this prospective 
cohort of patients (Table 1). 
Validation set and cause of deaths
EBV DNA was detectable in 62 of 112 CLL 
patients (55%), and was ≥ 2000 copies/µg DNA in 22%. 
As reported in Table S1, similarly to the learning set, 
EBV DNA load was significantly associated with CD38 
expression. 
The predictive value of EBV DNA load was 
confirmed in the validation set, both in terms of OS and 
TTFT (Figure S1). 
We observed 30 deaths in the learning set, and 32 
in the validation set. Causes of death were apparently 
similarly distributed among patients with different EBV 
Figure 3: Kaplan Meier plot for overall survival (OS, a and b) and time to first treatment (TTFT, c and d) in patients 
of the learning set with mutated (a and c) or unmutated (b and d) immunoglobulin heavy chain variable region (IGHV) 
mutational status.
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DNA load at CLL diagnosis. Second cancer was the cause 
of death in 5% and 12%, CLL progression in 42% and 
41%, infection in 8% and 9%, age-related complications 
in 13% and 14% of patients with low and high EBV DNA 
load, respectively. None of the differences was statistically 
significant.
Multivariate analysis
All significant variables from the univariate analysis 
comparisons were included in the multivariate analysis. 
Mutations of NOTCH1 were not included because of the 
low prevalence of mutated samples. In order to avoid 
the possible confounding effect derived by the choice of 
different cutoffs for EBV DNA load, we computed this 
variable as continuous measurement. 
In terms of OS, EBV DNA load resulted as the 
strongest independent predictive factor (P = .0004), 
together with IGHV mutational status (P = .02). Del17p/
P53 mutations were not significant in multivariate analysis 
due to their rarity (only 2 patients with del17p/P53 
mutation and high EBV DNA load, Table 1). The analysis 
identified Binet stage C (P = .0001), unmutated IGHV (P = 
.0005), and EBV DNA load as significant variables which 
independently predicted a shorter TTFT. Details are listed 
in Table 2. 
In accordance with Cox’s model results, a high EBV 
DNA load significantly predicted for poor OS and TTFT 
in both IGHV mutated and unmutated patients (Figure 3). 
The Cox model confirmed the independence of EBV DNA 
load and IGHV mutational status also in the validation 
set (hazard ratio 2.738, P = .005; hazard ratio 3.484, P = 
Table 1: Clinical and biological characteristics of 220 patients with chronic lymphocytic leukemia at disease 
presentation, then divided according to EBV DNA viral load (copies/µg DNA)
All Pts 
N = 220
EBV DNA ≥ 2000 
N = 43
EBV DNA < 2000 
N = 177 P-Value
Median age, years (range) 65 (30-86) 66 (47-86) 65 (30-83) 0.09*
Female gender 74 (34%) 19 (44%) 55 (31%) 0.10
Median lymphocyte count,
 x103/mmc (range) 9.1 (3.5-345) 8.1 (3.5-345) 10 (4.8-296) 0.24*
Richter’s transformation 8 (4%) 3 (7%) 5 (3%) 0.17
Second cancer 11 (5%) 3 (7%) 8 (5%) 0.47
BINET stage
A 171 (78%) 32 (74%) 139 (78%) 0.56
B 35 (16%) 9 (21%) 26 (15%) 0.31
C 14 (6%) 2 (5%) 12 (7%) 0.60
FISH°
Normal 68 (39%) 11 (33%) 57 (41%) 0.43
del13q 64 (37%) 10 (30%) 54 (39%) 0.37
12+ 13 (8%) 3 (9%) 10 (7%) 0.48
del11q 15 (9%) 7 (21%) 8 (6%) 0.004
del17p 5 (3%) 1 (3%) 4 (3%) 0.95
IGHV mutational status°
Unmutated IGHV 79 (41%) 20 (53%) 59 (38%) 0.10
Immunophenotype
CD38+ 63 (29%) 21 (49%) 42 (24%) 0.003
ZAP70+° 92 (53%) 22 (61%) 70 (51%) 0.30
CD49d+° 49 (35%) 10 (36%) 39 (35%) 0.95
Gene mutations°
P53 11 (6%) 1 (3%) 10 (6%) 0.236
NOTCH1 9 (4%) 4 (10%) 5 (3%) 0.05
SF3B1 14 (7%) 2 (6%) 12 (8%) 0.73
MYD88 6 (3%) 1 (3%) 5 (3%) 0.95
BIRC3 4 (3%) 0 (0%) 4 (3%) 0.35
Abbreviations: FISH: fluorescence in situ hybridization according to the hierarchical risk model; del13q: deletion in 
chromosome 13q14; del11q: deletion in chromosome 11q23; del17p: deletion in chromosome 17p12; +12: trisomy 12; 
IGHV: immunoglobulin heavy chain variable region genes. *Calculated with the Mann-Whitney test; °FISH available in 
173 patients, IGHV mutational status in 192, immunophenotype for ZAP70 in 172, CD49d in 139, P53 mutations in 207, 
NOTCH1 mutations in 204, SF3B1, MYD88, and BIRC3 mutations in 193.
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.0007, respectively).
EBV DNA load as continuous variable
As Cox model indicated that EBV DNA load was 
predictive as continuous variable, and given that EBV 
DNA load varied widely from patient to patient (range 
0-36449), we analyzed the impact of increasing levels of 
EBV DNA load on OS. When patients were divided in 
three groups according to frequency distribution of EBV 
DNA load (10th to 25th vs 25th to 90th vs >90th percentile), we 
observed a progressive impairment of OS curves (Figure 
4). Of note, patients with EBV DNA load ≥5000 copies/µg 
DNA (21, 10%) had an extremely poor 5-years OS of 50% 
± 12% vs 95% ± 3% for patients with EBV DNA load of 0 
(P < .0001) vs 80% ± 5% for those with EBV DNA load of 
1 to 4999. Again, as shown in Figure 4b-4c, results were 
independent of IGHV mutational status. 
DISCUSSION
In this study, we present for the first time an analysis 
on the clinical significance of EBV DNA load in patients 
with CLL at disease presentation. We have shown that 
EBV DNA load, tested in MNC, is detectable in more 
than half of patients, and that high levels (≥ 2000 copies/
µg DNA) are found in one fifth of patients. We found 
that EBV DNA load had a strong relationship with OS. 
The predictive value of viral load was independent of 
commonly recognized prognostic factors, and increasing 
levels of EBV DNA load were directly associated to worse 
outcome. Patients with EBV DNA ≥ 2000 copies/µg DNA 
had a 5-years OS of 67% ± 8%, which resembled patients 
with del17p/P53 gene mutation (5-years OS of 60% ± 
Figure 4: Kaplan Meier plot for overall survival (OS) of all patients from the learning set pooled on the basis of 
different EBV DNA loads (a). Patients with mutated immunoglobulin heavy chain variable region (IGHV) mutational status (b), and 
patients with unmutated IGHV (c) are shown. Reported P-values refer to comparison between EBV DNA ≥ 5000 copies/µg DNA and EBV 
DNA = 0 copies/µg DNA. P-values between EBV DNA = 1 to 4999 and EBV DNA ≥ 5000 copies/µg DNA in patients with mutated and 
unmutated IGHV were .001 and .04, respectively. All other differences were not statistically significant.
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16%) or patients with unmutated IGHV (5-years OS 69% 
± 6%). An independent retrospective series of patients 
with longer follow-up corroborated our findings. 
Our study has the merit of analysing a prospective 
series (learning set), avoiding bias related to patients 
selection. Despite the relatively short follow up for 
this indolent disease (54 months), the discriminating 
power of EBV DNA on OS appeared relevant. Since 
EBV replication is known to be related to severe 
immunosuppression, we hypothesized that the excess 
of deaths in patients with high EBV DNA load was due 
to infections or second tumors. However, deaths due to 
infections were 9% and 8% in patients with high or low 
EBV DNA load, respectively, while fatal second cancers 
were observed in 12% of patients with high EBV DNA 
and in 5% of patients with low EBV DNA load (P = .25). 
The poor prognosis conferred by high EBV DNA load was 
attributable, at least in part, to shorter TTFT (P = .0008), 
reflecting a more pronounced tumor aggressiveness, 
regardless of clinical stage at diagnosis (Binet A, B or 
C). Moreover, no significant relationship between EBV 
DNA load and age, or unmutated IGHV was observed. 
These findings suggest that EBV may not be a mere 
manifestation of the underlying immunosuppression 
associated with CLL, although further studies are needed 
to clarify this. 
So far, molecular detection of EBV DNA in 
circulating MNC or plasma of patients with CLL had not 
been consistently reported in the literature. Hermouet et 
al. [20] reported that 11 of 21 patients (52%) with CLL 
had measurable EBV DNA load in peripheral blood 
lymphocytes by a real-time PCR assay. More recently, 
a study from Poland found detectable EBV-DNA load 
in mononuclear cells of 54% patients with CLL [21]. 
Similarly to our findings, an association between higher 
EBV load, CD38 expression and del11q, together with a 
shorter treatment-free survival was reported.
We acknowledge that our observations cannot 
define the biological role of EBV in CLL. Further 
studies are needed, as it has been done in EBV-driven 
lymphoproliferative disorders [3-5]. We observed that 
EBV DNA was detectable in sorted CLL B-lymphocytes 
in five patients at similar levels than in MNC, while it 
was consistently undetectable in the plasma of 20 patients 
with either high or low EBV DNA load. This indicates that 
EBV may latently infect CLL B-cells, since the absence 
of DNA in plasma samples argues against an active lytic 
infection. At our cut-off value (2000 copies/µg DNA), 
roughly one cell out of 100 is infected by the virus (1 µg 
of DNA corresponds to approximately 100.000 infected 
cells or 200.000 EBV DNA copies). However, since EBV 
does not behave as a normal gene, and each cell could 
contain more than one viral genome, 2000 copies/ug 
DNA may correspond to less than one infected cell every 
100. Therefore, we can speculate that a relatively small 
number of CLL B-cells is infected by the virus at disease 
presentation, and that this EBV-related sub-clone would 
subsequently expand conditioning B-cells proliferation 
and the microenvironment. When latently infecting 
B lymphocytes EBV induces sustained telomerase 
activity [22], which is known to confer to B-CLL cases 
an aggressive clinical behaviour [23]. This link between 
EBV and telomerase may represent an explanation to the 
accelerated clinical course we have described in patients 
with high EBV DNA load. Longitudinal monitoring of 
EBV DNA load at different time points during CLL course 
would be of key importance to verify this theory. On the 
other hand, the presence of EBV DNA at higher levels in 
some patients may merely represent a consequence of the 
deeper immunosuppression, which is known to enhance 
tumor aggressiveness. For this reason, an assessment of 
T-lymphocyte and natural killer cell count, together with 
immunoglobulines level is warranted in these patients.
The literature does not provide a consistent threshold 
Table 2: Multivariate Cox’s regression analysis for (a) time to first treatment and (b) overall survival
(a)
Parameter HR (CI 95%) P-value
Binet B or C 6.711 (2.457-18.518) 0.0001
CD49d positive 2.047 (0.977-4.285) 0.05
CD38 positive 1.152 (0.547-2.452) 0.71
Unmutated IGHV status 3.225 (1.568-6.622) 0.0005
del17p/P53 mutation 1.912 (0.814-4.498) 0.13
EBV DNA load 2.853 (1.242-5.239) 0.002
(b)
Parameter HR (CI 95%) P-value
Unmutated IGHV status 3.215 (1.121-9.259) 0.02
del17p/P53 mutation 2.136 (0.684-6.671) 0.19
EBV DNA load 5.690 (2.173-14.905) 0.0004
Abbreviations: HR: Hazard Ratio; CI: Confidence Interval; IGHV: immunoglobulin heavy chain variable region genes; 
del17p: deletion in chromosome 17p12.
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value corresponding to “high” EBV load, despite EBV is 
routinely investigated using sensitive and quantitative 
PCR methods, to relate virus loads to disease emergence 
and progression in several hematological malignancies 
including post-transplant lymphoproliferative disorders 
[24, 25]. We observed that 95% of our healthy subjects 
had EBV DNA load < 2000 copies/µg DNA, and we 
assumed this as a cut-off value to define high level. 
Similarly, Stevens et al. [19] found that MNC samples of 
healthy donors had EBV DNA load < 2000 copies/ml in 
almost all cases. This is consistent with previous studies 
that found EBV genome copy number in adults with latent 
EBV infection [24]. The variations in EBV DNA detection 
rates may be ascribed to the use of different assay systems, 
and to the lack of an agreed calibrator, specimen type, or 
unit adopted for reporting [25]. Obviating the need of a 
specific cut-off, EBV DNA load as a continuous variable 
was highly predictive in our series (Figure 4).
EBV has been well characterized in cases of 
Richter’s transformation of CLL, particularly those 
displaying abundant Reed – Sternberg type cells [26]. 
In some, but not all cases, the malignant transformation 
occurs in cells originating from the CLL clone. In 
other cases of patients heavily pre-treated with T cell 
suppressants such as fludarabine, Richter’s has been 
associated with the development of an unrelated EBV-
associated B-cell clone showing that EBV or other viruses 
could drive Richter’s transformation in some patients 
with CLL in the presence of impaired EBV-specific 
T-cell immunity [27, 14-16]. However, the precise role 
of EBV infection in Richter’s transformation remains 
to be determined. In our series we described 12 patients 
developing Richter’s transformation during follow-up (8 
in the learning set and 4 in the validation set). Four of 
these had EBV DNA load ≥ 2000 copies/µg DNA (Table 
1 and Table S1). Median EBV DNA load among patients 
with Richter’s transformation was higher (1232 copies/
µg DNA) than in patients without transformation (185 
copies/µg DNA), but this difference was not statistically 
significant (P = .16). It is conceivable that sample 
collection in our patients undergoing later transformation 
was obtained too early, thus hampering a more precise 
evaluation of EBV role in driving CLL transformation.
In summary, our analysis on prospective patients 
with CLL indicates that EBV is present in peripheral MNC 
in more than half of patients with newly diagnosed CLL. 
High levels of EBV DNA are associated with an aggressive 
clinical behavior and short survival. The independence of 
EBV DNA load from most widely recognized biological 
and clinical prognostic factors indicates that a quantitative 
test for EBV DNA load could be integrated in the initial 
evaluation of patients to better define their outcome. 
Further studies are needed to clarify whether EBV has an 
active role in enhancing CLL progression or is merely a 
manifestation of the underlying immunosuppressed state 
associated with the disease.
MATERIALS AND METHODS
Patients
A total of 220 consecutive patients with newly 
diagnosed CLL referred to two major Hematology 
Divisions (San Bortolo Hospital, Vicenza, and University 
Hospital, Verona), were enrolled between June 2007 
and December 2013, and followed prospectively. 
These patients constituted a learning set for prognostic 
considerations. A subsequent cohort was used for 
independent confirmation (validation set). In all patients 
biological material was collected at diagnosis, before 
receiving any cytotoxic treatment. All patients met the 
CLL diagnostic criteria of National Cancer Institute 
Working Group [18], and gave written informed consent to 
donate their blood and to have their clinical data collected 
into a dedicated database. Patients with monoclonal 
B-cell lymphocytosis (MBL) were excluded. The study 
was approved by the ethic review board of San Bortolo 
Hospital, as an ancillary study of the “CLL Veneto” 
project, which was started in 2007 as a prospective clinical 
and biological registry of incident patients diagnosed with 
CLL.
Clinical characteristics and treatment
The median age of patients enrolled in the learning 
set was 65 years (range 30-86 years), with a male/female 
ratio of 1.97. Clinical and biological characteristics are 
listed in Table 1. At the time of this analysis, median 
follow-up from CLL diagnosis was 54 months (range 
12-98). Overall, 81 patients (37%) received induction 
chemo-immunotherapy consisting of rituximab, 
fludarabine, cyclophosphamide in 36 (45%), rituximab 
and chlorambucil in 20 (25%), chlorambucil alone in 12 
(14%), and other immunochemotherapies in 13 (16%), 
following the guidelines of the CLL Veneto protocol, 
which were based on widely accepted guidelines in terms 
of treatment and visits of follow-up [18].
Blood processing, DNA and RNA extraction
At CLL diagnosis, we collected 20 mL of whole 
blood for each patient in EDTA-rinsed tubes. Plasma was 
obtained by centrifugation of samples. Peripheral blood 
MNC were isolated by Ficoll gradient, and were used for 
DNA and RNA extraction using QIAGEN spin-column 
kits and automatically extracted by QIAcube (Qiagen). 
Extracted DNA and RNA were then quantified by using 
the Nanodrop spectrophotometer (Thermo Scientific). 
Both plasma and nucleic acids were subsequently frozen 
at -80°C. 
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In five cases CLL B-cell subpopulations expressing 
CD19/CD5/CD23/CD20/CD43 were sorted by 
fluorescence-activated cell sorting (FACSAria II, Becton 
Dickinson, San Jose, CA) and DNA was extracted both 
from MNC and sorted B cells for comparison of EBV 
DNA load.
Real time polymerase chain reaction (PCR) for 
measuring EBV DNA
EBV DNA load was assessed by quantitative 
PCR using DNA extracted from plasma or MNC, and 
was expressed as number of DNA copies per µg of total 
extracted DNA (copies/µg DNA). Analysis were made 
by setting up real time PCR performed on Rotor-Gene Q 
(Qiagen) using artus EBV QS-RGQ kit (Qiagen) following 
the instructions provided by the company. The EBV RGQ 
Master contains reagents and enzymes for the specific 
amplification of a 97 bp region of the EBNA-1 gene. 
An internal control and external positive controls were 
included to monitor the efficiency of sample preparation 
and downstream assay. Further details are available at 
http://www.qiagen.com/resources.
Epstein-Barr virus serological pattern
The presence of serum immunoglobulin G (IgG) 
and IgM antibodies against the viral capsid antigen 
(VCA) was studied in 74 patients at CLL diagnosis using 
chemiluminescence immunoassay. Sixty-eight patients 
(92%) were IgG+/IgM, 4 (5%) were IgG+/IgM+, and 2 
(3%) were IgG-/IgM-.
Healthy subjects
Forty-one healthy subjects without signs or 
symptoms of recent or ongoing fever, no enlarged 
lymphnodes or infectious episodes were recruited among 
blood donors or volunteers, and their peripheral blood 
MNC were isolated tested for EBV DNA load. Sixteen 
were females and median age was 59 years old (range 32-
74). We included 20 subjects older than 60 to minimize 
age-related bias in comparison to CLL patients.
Validation set
For validation, we used an independent series of 
112 patients with CLL, diagnosed at San Bortolo Hospital 
between January 2001 and May 2007. This set included 
retrospective cases with available stored biological 
material at CLL diagnosis and follow-up data. Median 
follow-up from CLL diagnosis was 103 months (range 
14-168). Their clinical presentation and survival appeared 
representative to an unselected cohort of consecutive 
patients with CLL (Table S1) [18].
Phenotypical, molecular, and genetic analysis
CD49d, ZAP-70 and CD38 expression were 
assessed on peripheral blood samples by flow cytometry, 
as previously described [28]. Extracted RNA was used 
to assess immunoglobulin heavy chain variable region 
(IGHV) mutational status, and stereotypes of the B-cell 
receptor were determined by analyzing the complete 
sequence of the heavy-chain complementary-determining 
region 3 in 210 patients (137 from the learning set and 73 
from the validation set), as previously reported [29].
Cytogenetic abnormalities were evaluated by 
cytogenetic and fluorescence in situ hybridization (FISH) 
according to the hierarchical risk model of FISH anomalies 
[30]. The mutation hot spots of the TP53 (exons 4-9, 
including splicing sites; RefSeq NM_000546.5), NOTCH1 
(exon 34; including splicing sites; RefSeq NM_017617.2), 
SF3B1 (exons 14, 15, 16, 18, including splice sites; 
RefSeq NM_012433.2), MYD88 (exons 3, 5, including 
splicing sites; RefSeq NM_002468.4), and BIRC3 (exons 
6-9, including splicing sites; RefSeq NM_001165.4) genes 
were analyzed on extracted DNA by PCR amplification 
and DNA direct sequencing of high-molecular-weight 
genomic DNA, as previously described [31].
Statistical analysis
EBV DNA load ≥ 2000 copies/µg DNA, 
corresponding to the 95th percentile of healthy subjects, 
was defined as high value, in keeping with data of the 
literature [19]. 
Overall survival (OS), defined as the time interval 
between CLL diagnosis and last follow-up or death for 
any cause, was considered the primary outcome of the 
study. Time-to-first-treatment (TTFT) was defined as the 
time interval between the date of presentation and date 
of first CLL treatment. Patients who did not receive any 
treatment during follow-up were censored at their last 
follow-up date. Actuarial OS and TTFT were estimated 
by the Kaplan-Meier method [32] and differences were 
analyzed by the log rank test. Proportional Cox Hazard 
Model was used for multivariate analysis [33].
The comparison of clinical and biological features 
between patients with high vs low load was carried out 
with the χ2 test or with the nonparametric Mann-Whitney 
test, as appropriate. The Kolmogorov–Smirnov test (K–S 
test) was used to define the distribution of the EBV DNA 
load as continuous variable. All variables found to have 
a P value less than or equal to .05 were considered to be 
statistically significant. All statistical calculations were 
performed using StatView (Abacus Concepts, Berkeley, 
CA).
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